Want the short version?
Ask OQRO reads the filings behind this page and answers in plain words, with a link to each source.
Ask OQRO is part of OQRO Pro. Everything else on OQRO is free.
Ask OQRO reads the filings behind this page and answers in plain words, with a link to each source.
Ask OQRO is part of OQRO Pro. Everything else on OQRO is free.
Only to see which pages are hard to use, so we can fix them. Nothing is used for ads, and what you type stays hidden (Microsoft Clarity, PostHog). Privacy Policy
Richard Stark is Director at Renovorx. OQRO lists 1 transaction filed with the SEC under this name, the latest on Nov 20, 2026, each linked to the official Form 4.
Director
Disclosures on record
1
Companies involved
1
RenovorxRNXT
Nov 18, 2026129Kdisclosed Nov 20
DetailsOfficial recordRichard Stark has no open-market purchase on record since 2012. Sales in 3 of the 15 years since 2012.
Richard Stark reported 0 open-market purchases and 4 sales since 2012; no open-market purchase.
| Year | Bought | Sold |
|---|---|---|
| 2017 | — | $446K1×1 trade |
| 2015 | — | $335K1×1 trade |
| 2012 | — | $59K2×2 trades |
Open-market purchases (code P) and sales (code S) on Forms 4 and 5. Up to Sep 2024 from the SEC's Insider Transactions Data Sets; since Oct 2024 from each filing as it is published. A trade filed twice (an amendment) counts once. Dollar totals use the price the filer reported; lines with no price count as trades without a value.
Richard Stark has no open-market purchase on record since 2012. Sales in 3 of the 15 years since 2012.
In SEC filings since 2012: no open-market purchase is on record; the latest open-market sale is from 2017.
Angiodynamics (ANGO), from 2012 to 2017: 0 purchases and 4 sales.
Richard Stark reported 0 open-market purchases and 4 sales here, 2012 to 2017.
Closing prices and the companies' last annual figures; a − or + is a fact of the close, not a forecast.